# SYVN1

## Overview
SYVN1 is a gene that encodes the protein synoviolin 1, an E3 ubiquitin ligase that plays a pivotal role in the endoplasmic reticulum-associated degradation (ERAD) pathway. As a member of the ubiquitin-proteasome system, synoviolin 1 is involved in tagging misfolded proteins for degradation, thereby maintaining protein quality control and cellular homeostasis (Gao2008Synoviolin; Aratani2017Inhibitory). This protein is primarily localized in the endoplasmic reticulum, where it helps mitigate stress-induced apoptosis by managing the degradation of misfolded proteins, thus regulating ER stress signals (Gao2008Synoviolin). Synoviolin 1's interactions with various proteins, including tumor suppressors and enzymes, underscore its significance in cellular processes such as cell cycle regulation, apoptosis, and stress response. The gene's dysregulation has been implicated in several diseases, including cancer and rheumatoid arthritis, highlighting its potential as a therapeutic target (Duan2024SYVN1; Xie2023SYVN1).

## Function
SYVN1, also known as synoviolin 1, is an E3 ubiquitin ligase that plays a critical role in the endoplasmic reticulum-associated degradation (ERAD) pathway. This protein is involved in the ubiquitination process, which tags misfolded proteins for degradation, thereby maintaining protein quality control and cellular homeostasis (Gao2008Synoviolin; Aratani2017Inhibitory). SYVN1 is active in the endoplasmic reticulum, where it helps prevent stress-induced apoptosis by degrading misfolded proteins, thus contributing to the regulation of ER stress signals (Gao2008Synoviolin).

In healthy human cells, SYVN1 modulates the degradation of several key proteins, including the tumor suppressor p53. By ubiquitinating p53, SYVN1 regulates its levels and activity, which is crucial for controlling cell cycle and apoptosis (Wu2011Silencing). The interaction between SYVN1 and other proteins, such as PADI4, suggests a complex regulatory mechanism where SYVN1's ubiquitination activity can be modulated, impacting processes like protein degradation and cellular stress responses (Aratani2017Inhibitory). This modulation is essential for maintaining cellular homeostasis and preventing the accumulation of potentially harmful proteins.

## Clinical Significance
Alterations in the expression or function of the SYVN1 gene, also known as synoviolin 1, have been implicated in various diseases, particularly cancers and rheumatoid arthritis. In esophageal squamous cell carcinoma (ESCC), SYVN1 is overexpressed, suggesting a role in tumorigenesis by promoting the degradation of tumor suppressors such as SIRT2 and PTEN (Mangalaparthi2023Molecular). In hepatocellular carcinoma (HCC), SYVN1 facilitates immune evasion and metastasis by ubiquitinating FoxO1, leading to increased β-catenin nuclear translocation and PD-L1 expression (Xie2023SYVN1). This process contributes to tumor progression and highlights SYVN1 as a potential therapeutic target in HCC (Xie2023SYVN1).

In breast cancer, particularly triple-negative breast cancer (TNBC), SYVN1 is upregulated in response to treatment with VNLG-152R, leading to the degradation of MNK1/2 and affecting oncogenic pathways (Thankan2023VNLG152R). This suggests a tumor-suppressive role for SYVN1 in this context, contrasting with its oncogenic role in other cancers.

In rheumatoid arthritis, SYVN1 is involved in synovial hyperplasia by alleviating ER stress and degrading p53, thus preventing apoptosis (Yamasaki2007The). This function underscores its potential as a therapeutic target in proliferative diseases like rheumatoid arthritis (Tsuchimochi2005Identification).

## Interactions
SYVN1, also known as synoviolin 1, is an E3 ubiquitin ligase that participates in various protein interactions, playing a significant role in cellular processes. It interacts with peptidyl-arginine deiminase 4 (PADI4), an enzyme involved in protein citrullination, which is associated with rheumatoid arthritis. This interaction is not dependent on PADI4's enzymatic activity but rather on stoichiometric effects, suggesting a role in suppressing protein ubiquitination (Aratani2017Inhibitory).

SYVN1 also interacts with the tumor suppressor protein p53, sequestering it in the cytoplasm and promoting its degradation. This interaction is crucial in regulating p53 activity, particularly under conditions of endoplasmic reticulum stress, where SYVN1 is upregulated to manage unfolded proteins and delay apoptosis (Yamasaki2007The; Vermeulen2022Evaluation).

In the context of cancer, SYVN1 interacts with MNK1/2 proteins, facilitating their ubiquitin-proteasomal degradation, which is significant in breast cancer treatment strategies (Thankan2023VNLG152R). Additionally, SYVN1 interacts with HMGB1 in papillary thyroid carcinoma, leading to its degradation and affecting tumor progression (Duan2024SYVN1). These interactions highlight SYVN1's role in various cellular pathways and its potential as a therapeutic target.


## References


[1. (Wu2011Silencing) Zchong-Zcho Wu, Nian-Kang Sun, Kun-Yi Chien, and Chuck C.-K. Chao. Silencing of the snare protein napa sensitizes cancer cells to cisplatin by inducing erk1/2 signaling, synoviolin ubiquitination and p53 accumulation. Biochemical Pharmacology, 82(11):1630–1640, December 2011. URL: http://dx.doi.org/10.1016/j.bcp.2011.08.018, doi:10.1016/j.bcp.2011.08.018. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2011.08.018)

[2. (Mangalaparthi2023Molecular) Kiran K. Mangalaparthi, Krishna Patel, Aafaque Ahmad Khan, Bipin Nair, Rekha V. Kumar, Thottethodi Subrahmanya Keshav Prasad, David Sidransky, Aditi Chatterjee, Akhilesh Pandey, and Harsha Gowda. Molecular characterization of esophageal squamous cell carcinoma using quantitative proteomics. Cancers, 15(13):3302, June 2023. URL: http://dx.doi.org/10.3390/cancers15133302, doi:10.3390/cancers15133302. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers15133302)

[3. (Yamasaki2007The) Satoshi Yamasaki, Naoko Yagishita, Kusuki Nishioka, and Toshihiro Nakajima. The roles of synoviolin in crosstalk between endoplasmic reticulum stress-induced apoptosis and p53 pathway. Cell Cycle, 6(11):1319–1323, June 2007. URL: http://dx.doi.org/10.4161/cc.6.11.4277, doi:10.4161/cc.6.11.4277. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.4161/cc.6.11.4277)

[4. (Thankan2023VNLG152R) Retheesh S. Thankan, Elizabeth Thomas, Puranik Purushottamachar, David J. Weber, Vidya P. Ramamurthy, Weiliang Huang, Maureen A. Kane, and Vincent C. O. Njar. Vnlg-152r and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating e3 ligase synoviolin 1 (syvn1) and inducing proteasomal degradation of mnk1/2. Frontiers in Oncology, September 2023. URL: http://dx.doi.org/10.3389/fonc.2023.1240996, doi:10.3389/fonc.2023.1240996. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2023.1240996)

[5. (Tsuchimochi2005Identification) Kaneyuki Tsuchimochi, Naoko Yagishita, Satoshi Yamasaki, Tetsuya Amano, Yukihiro Kato, Ko-ichi Kawahara, Satoko Aratani, Hidetoshi Fujita, Fengyun Ji, Akiko Sugiura, Toshihiko Izumi, Asako Sugamiya, Ikuro Maruyama, Akiyoshi Fukamizu, Setsuro Komiya, Kusuki Nishioka, and Toshihiro Nakajima. Identification of a crucial site for synoviolin expression. Molecular and Cellular Biology, 25(16):7344–7356, August 2005. URL: http://dx.doi.org/10.1128/mcb.25.16.7344-7356.2005, doi:10.1128/mcb.25.16.7344-7356.2005. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.25.16.7344-7356.2005)

[6. (Gao2008Synoviolin) Beixue Gao, Sang‐Myeong Lee, An Chen, Jinping Zhang, Donna D Zhang, Krishnaswamy Kannan, Robert A Ortmann, and Deyu Fang. Synoviolin promotes ire1 ubiquitination and degradation in synovial fibroblasts from mice with collagen‐induced arthritis. EMBO reports, 9(5):480–485, March 2008. URL: http://dx.doi.org/10.1038/embor.2008.37, doi:10.1038/embor.2008.37. This article has 93 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/embor.2008.37)

[7. (Duan2024SYVN1) Fei Duan, Fanli Kong, Taifeng Jiang, and Hongbing Liu. Syvn1 modulates papillary thyroid carcinoma progression by destabilizing hmgb1. Cell Division, April 2024. URL: http://dx.doi.org/10.1186/s13008-024-00121-1, doi:10.1186/s13008-024-00121-1. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13008-024-00121-1)

[8. (Aratani2017Inhibitory) Satoko Aratani, Hidetoshi Fujita, Naoko Yagishita, Yoshihisa Yamano, Yukari Okubo, Kusuki Nishioka, and Toshihiro Nakajima. Inhibitory effects of ubiquitination of synoviolin by padi4. Molecular Medicine Reports, 16(6):9203–9209, October 2017. URL: http://dx.doi.org/10.3892/mmr.2017.7764, doi:10.3892/mmr.2017.7764. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2017.7764)

[9. (Xie2023SYVN1) Wei Xie, Lei Shi, Hu Quan, Hua Xiao, Jie Chen, Jia Liu, Jean de Dieu Habimana, Rongqi Huang, Jia Luo, Pan Chen, and Zhiyuan Li. Syvn1 ubiquitinates foxo1 to induce β-catenin nuclear translocation, pd-l1-mediated metastasis, and immune evasion of hepatocellular carcinoma. Cellular Oncology, 46(5):1285–1299, April 2023. URL: http://dx.doi.org/10.1007/s13402-023-00811-y, doi:10.1007/s13402-023-00811-y. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13402-023-00811-y)

[10. (Vermeulen2022Evaluation) Christie Vermeulen, Tereza Brachtlova, Nikki Tol, Ida H. van der Meulen-Muileman, Jasmina Hodzic, Henri J. van de Vrugt, and Victor W. van Beusechem. Evaluation of a novel oncolytic adenovirus silencing syvn1. International Journal of Molecular Sciences, 23(23):15430, December 2022. URL: http://dx.doi.org/10.3390/ijms232315430, doi:10.3390/ijms232315430. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms232315430)